Medical Need

Diabetic foot ulcer & chronic wounds

Fuss_Wunde

Pressing need for novel and effective therapies

  • Leading cause of hospitalizations in diabetes
  • 75% of all amputations are diabetic patients
  • Only 21% of patients with lower leg amputation survive a 5 year period
  • 50 Mio out of 370 Mio diabetics patients are affected
  • Huge burden to patients and payors (€ 12 bn p.a.)

Current Therapies with Limited Success

  • Negative Pressure
  • Skin Substitutes
  • Oxygen
  • Growth factors (Becaplermin/only USA)

Strategic Options for the Future:

Outlicensing of other ground-breaking

TOPADUR medical pipeline compounds :

IP Rights of TOPADUR: 

  • Strong IP position

OUR MEDICAL COMPOUND CANDIDATES PORTFOLIO IN 2020:

SLIDE_2020_RD-Portfolio_2

– TOPADUR’s leading drug, TOP-N53 enables the healing of chronic wounds such as diabetic foot ulcer (DFU) and orphan ulcera. It will enter clinical trials in spring 2020.

TOP-N53 has the potential to be a breakthrough medication in preventing diseases with high unmet medical need, with the possibility to save more than one million foot amputations every year and to decrease associated mortality.

TOP-V122 and TOP-T5 are new candidate drugs in pre-clinical stage, predicted to increase ocular blood microcirculation and neuroprotection. These medical compounds have the potential to become breakthrough therapies in preventing blindness in several ophthalmic diseases.

– TOP-N44 is a drug candidate in preclinical development, which we expect, based on preclinical data, to inhibit scar formation after burn wounds.

We demonstrated in a recent proof of concept that TOP-M119 is a potent hair growth promoter. Since loss of sensory hair cells in the inner ear is the main reason for age dependent hearing loss, we plan to evaluate the potential of this drug candidate in animal models for such indications. Furthermore addtional promissing scientific possibilities in the area of HNSCC & colon cancer (cancer stem cells) are being exploited in 2020.

Scar & keloid prevention

SCAREphoto3

Strong Need for Innovative, Antifibrotic and Anti-Inflammatory Treatments

  • Up to 15% of general population affected with hypertrophic scars following wounds
  • 70% of patients with burns develop hypertrophic scars
  • Keloids occur to 5-16% in high risk populations e.g. asian, african, hispanic
  • € 12 bn treatment costs p.a.

 

Current Therapies with Limited Success

  • Corticosteroids (triamcinolone)
  • 5-Fluorouracil
  • Cryotherapy
  • Surgery